Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Intravenous TP-6076 in Healthy Subjects
NCT03691584Phase 1Completed
- Sponsor
- Tetraphase Therapeutics
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TP-6076 in Acinetobacter baumannii infection, bacterial infection and pneumonia, sponsored by Tetraphase Therapeutics. Primary endpoints: Concentrations of TP-6076 in plasma at 24 hours, Concentrations of TP-6076 in epithelial lining fluid (ELF) at 24 hours and 3 more. Started Nov 2018; status: completed.
02
Drugs
TP-6076
03
Conditions
Acinetobacter baumannii infectionbacterial infectionpneumonia
Beyond the preview
Go deeper on NCT03691584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691584.